Pleiotropic Effects of Statins–Basic Research and Clinical Perspectives–

Q Zhou, JK Liao - Circulation journal, 2010 - jstage.jst.go.jp
Figure 2. Regulation of the Rho GTPase cycle. Rho protein cycle between an inactive GDP-
bound and an active GTP-bound state. Inhibition of the mevalonate synthesis by statins …

Obesity, inflammation, and cardiovascular risk

P Mathieu, I Lemieux… - Clinical pharmacology & …, 2010 - Wiley Online Library
Obesity, a highly prevalent condition, is heterogeneous with regard to its impact on
cardiovascular disease (CVD) risk. Epidemiological observations and metabolic …

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a …

FJ Raal, RD Santos, DJ Blom, AD Marais, MJ Charng… - The Lancet, 2010 - thelancet.com
Background Homozygous familial hypercholesterolaemia is a rare genetic disorder in which
both LDL-receptor alleles are defective, resulting in very high concentrations of LDL …

Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population

J Eugen‐Olsen, O Andersen… - Journal of internal …, 2010 - Wiley Online Library
Eugen‐Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen
J, Pielak T, Møller LN, Jeppesen J, Lyngbæk S, Fenger M, Olsen MH, Hildebrandt PR, Borch …

Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study

M Ai, S Otokozawa, BF Asztalos, Y Ito… - Clinical …, 2010 - academic.oup.com
Objective: We sought to establish reference values for a new direct assay for small dense
LDL cholesterol (sdLDL-C) and to measure sdLDL-C concentrations in patients with …

Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation

A Denes, P Thornton, NJ Rothwell, SM Allan - Brain, behavior, and …, 2010 - Elsevier
Inflammation is a classical host defence response to infection and injury that has many
beneficial effects. However, inappropriate (in time, place and magnitude) inflammation is …

C-reactive protein is a mediator of cardiovascular disease

RJ Bisoendial, SM Boekholdt, M Vergeer… - European heart …, 2010 - academic.oup.com
C-reactive protein is postulated to embody an index that can reflect cardiovascular risk and
can be used to independently predict major cardiovascular events and mortality. On the …

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

PM Ridker, J Genest, SM Boekholdt, P Libby, AM Gotto… - The Lancet, 2010 - thelancet.com
Background HDL-cholesterol concentrations are inversely associated with occurrence of
cardiovascular events. We addressed, using the JUPITER trial cohort, whether this …

Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory …

RJ Glynn, W Koenig, BG Nordestgaard… - Annals of internal …, 2010 - acpjournals.org
Background: Randomized data on statins for primary prevention in older persons are limited,
and the relative hazard of cardiovascular disease associated with an elevated cholesterol …

Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the …

PM Ridker, J MacFadyen, M Cressman… - Journal of the American …, 2010 - jacc.org
Objectives: We evaluated the efficacy of statin therapy in primary prevention among
individuals with moderate chronic kidney disease (CKD). Background: Whether patents with …